Rep. Lisa C. McClain Sells Merit Medical Systems, Inc. (NASDAQ:MMSI) Stock

Key Points

• Representative Lisa C. McClain sold shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) worth between $1,001 and $15,000 on September 25th, as disclosed in a filing on October 22nd.
• The stock of Merit Medical Systems has decreased by 1.4%, with a current price of $83.33, and has a market cap of $4.93 billion.
• Analyst ratings for MMSI stock indicate a consensus of Buy with an average target price of $106.50 and several recent upgrades and downgrades reflecting a generally positive outlook.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Merit Medical Systems, Inc. NASDAQ: MMSI. In a filing disclosed on October 22nd, the Representative disclosed that they had sold between $1,001 and $15,000 in Merit Medical Systems stock on September 25th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of FMC NYSE: FMC on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Darden Restaurants NYSE: DRI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of ASML NASDAQ: ASML on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Kenvue NYSE: KVUE on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Beacon Financial NYSE: BBT on 9/25/2025.
• Sold $1,001 - $15,000 in shares of British American Tobacco NYSE: BTI on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of Rollins NYSE: ROL on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of SAP NYSE: SAP on 9/25/2025.
• Purchased $1,001 - $15,000 in shares of MGP Ingredients NASDAQ: MGPI on 9/25/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 9/25/2025.

Merit Medical Systems Stock Down 1.4%

Shares of MMSI stock opened at $83.33 on Friday. Merit Medical Systems, Inc. has a 12 month low of $78.12 and a 12 month high of $111.45. The stock has a market cap of $4.93 billion, a P/E ratio of 42.30, a P/E/G ratio of 2.72 and a beta of 0.58. The company has a current ratio of 4.09, a quick ratio of 2.66 and a debt-to-equity ratio of 0.49. The company has a 50 day simple moving average of $85.30 and a two-hundred day simple moving average of $89.61.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical instruments supplier reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.16. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. The business had revenue of $382.46 million during the quarter, compared to analysts' expectations of $372.47 million. During the same period in the prior year, the company earned $0.92 earnings per share. The firm's revenue was up 13.2% on a year-over-year basis. On average, research analysts expect that Merit Medical Systems, Inc. will post 3.37 earnings per share for the current year.

Insider Buying and Selling at Merit Medical Systems

In related news, Director Lynne N. Ward sold 3,000 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $88.56, for a total transaction of $265,680.00. Following the completion of the transaction, the director owned 12,809 shares in the company, valued at approximately $1,134,365.04. This represents a 18.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company's stock.

Hedge Funds Weigh In On Merit Medical Systems

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Merit Medical Systems by 1.1% during the second quarter. State Street Corp now owns 2,218,432 shares of the medical instruments supplier's stock worth $207,379,000 after acquiring an additional 24,569 shares during the last quarter. Invesco Ltd. boosted its position in shares of Merit Medical Systems by 16.4% during the first quarter. Invesco Ltd. now owns 1,787,289 shares of the medical instruments supplier's stock worth $188,934,000 after acquiring an additional 251,821 shares during the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in shares of Merit Medical Systems by 8.2% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,766,711 shares of the medical instruments supplier's stock worth $186,759,000 after acquiring an additional 133,465 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Merit Medical Systems by 2.8% during the second quarter. Geode Capital Management LLC now owns 1,437,397 shares of the medical instruments supplier's stock worth $134,384,000 after acquiring an additional 39,620 shares during the last quarter. Finally, Maverick Capital Ltd. boosted its position in shares of Merit Medical Systems by 8.4% during the second quarter. Maverick Capital Ltd. now owns 1,379,408 shares of the medical instruments supplier's stock worth $128,947,000 after acquiring an additional 106,897 shares during the last quarter. Institutional investors own 99.66% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Piper Sandler reduced their target price on shares of Merit Medical Systems from $110.00 to $105.00 and set an "overweight" rating for the company in a report on Thursday, July 31st. Weiss Ratings reissued a "hold (c+)" rating on shares of Merit Medical Systems in a research note on Wednesday, October 8th. Barrington Research reissued an "outperform" rating and issued a $103.00 price objective on shares of Merit Medical Systems in a research note on Tuesday, October 7th. Needham & Company LLC reissued a "buy" rating and issued a $108.00 price objective on shares of Merit Medical Systems in a research note on Friday, July 18th. Finally, Raymond James Financial reduced their price objective on shares of Merit Medical Systems from $108.00 to $102.00 and set an "outperform" rating for the company in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $106.50.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.